Shots:

•  The P-III study involves assessing of SB11 vs reference product- LUCENTIS in monthly injections (0.5mg) in 705 patients in a ratio (1:1) with nAMD
• The P-III study results demonstrated equivalent efficacy in terms of change in BCVA @8wk. and CST @4wk.- LS change in BCVA (6.2 vs 7.0 letters)- LS change in CST ( −108.4μm vs −100.1μm)- AEs (66.0% vs 66.9%). The data was to be presented at ARVO 2020 which has been cancelled due to COVID-19
• Additionally- in Nov’2019- Samsung collaborated with Biogen for two ophthalmology biosimilar candidates- SB11 (ranibizumab) and SB15 (aflibercept)- in the US- Canada- EU- Japan- and Australia

Click here to read full press release/ article | Ref: Samsung Bioepis | Image: Samsung Bioepis

Related News: Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer